Potent Cross-neutralizing Antibodies Reveal Vulnerabilities of Henipavirus Fusion Glycoprotein., PMID:40298900
Development and Validation of a Differentiating Infected from Vaccinated Animals (DIVA) Enzyme-Linked Immunosorbent Assay (ELISA) Strategy for Distinguishing Between Hendra-Infected and Vaccinated Horses., PMID:40143282
Serological and molecular analysis of henipavirus infections in synanthropic fruit bat and rodent populations in the Centre and North regions of Cameroon (2018-2020)., PMID:39994638
Functional assessment of the glycoproteins of a novel Hendra virus variant reveals contrasting fusogenic capacities of the receptor-binding and fusion glycoproteins., PMID:39704501
Establishing an immune correlate of protection for Nipah virus in nonhuman primates., PMID:39702562
An attachment glycoprotein nanoparticle elicits broadly neutralizing antibodies and protects against lethal Nipah virus infection., PMID:39217188
Measures to prevent and treat Nipah virus disease: research priorities for 2024-29., PMID:38964362
Nano-Assembled Polyphosphazene Delivery System Enables Effective Intranasal Immunization with Nipah Virus Subunit Vaccine., PMID:38812435
A potent Henipavirus cross-neutralizing antibody reveals a dynamic fusion-triggering pattern of the G-tetramer., PMID:38773072
An in vivo BSL-2 model for henipavirus infection based on bioluminescence imaging of recombinant Cedar virus replication in mice., PMID:38770087
Evaluation of the immunogenicity of an mRNA vectored Nipah virus vaccine candidate in pigs., PMID:38726013
Structure and design of Langya virus glycoprotein antigens., PMID:38593070
Therapeutic administration of a cross-reactive mAb targeting the fusion glycoprotein of Nipah virus protects nonhuman primates., PMID:38569014
Prefusion stabilization of the Hendra and Langya virus F proteins., PMID:38214525
Recombinant Soluble Henipavirus Glycoprotein Preparation., PMID:37610572
Nipah virus attachment glycoprotein ectodomain delivered by type 5 adenovirus vector elicits broad immune response against NiV and HeV., PMID:37577376
A Recombinant Chimeric Cedar Virus-Based Surrogate Neutralization Assay Platform for Pathogenic Henipaviruses., PMID:37243163
Structural basis for antibody recognition of vulnerable epitopes on Nipah virus F protein., PMID:36932063
Development and laboratory evaluation of a competitive ELISA for serodiagnosis of Nipah and Hendra virus infection using recombinant Nipah glycoproteins and a monoclonal antibody., PMID:36816187
Serological Hendra Virus Diagnostics Using an Indirect ELISA-Based DIVA Approach with Recombinant Hendra G and N Proteins., PMID:35744614
Potent monoclonal antibody-mediated neutralization of a divergent Hendra virus variant., PMID:35617431
Architecture and antigenicity of the Nipah virus attachment glycoprotein., PMID:35239409
Sero-Monitoring of Horses Demonstrates the Equivac® HeV Hendra Virus Vaccine to Be Highly Effective in Inducing Neutralising Antibody Titres., PMID:34358146
Broadly neutralizing antibody cocktails targeting Nipah virus and Hendra virus fusion glycoproteins., PMID:33927387
Prediction of the binding interface between monoclonal antibody m102.4 and Nipah attachment glycoprotein using structure-guided alanine scanning and computational docking., PMID:33106487
Vaccines to Emerging Viruses: Nipah and Hendra., PMID:32991264
Fc-Based Recombinant Henipavirus Vaccines Elicit Broad Neutralizing Antibody Responses in Mice., PMID:32340278
Serological Evidence for Henipa-like and Filo-like Viruses in Trinidad Bats., PMID:32034942
Safety, tolerability, pharmacokinetics, and immunogenicity of a human monoclonal antibody targeting the G glycoprotein of henipaviruses in healthy adults: a first-in-human, randomised, controlled, phase 1 study., PMID:32027842
A structural basis for antibody-mediated neutralization of Nipah virus reveals a site of vulnerability at the fusion glycoprotein apex., PMID:31767754
A Cross-Reactive Humanized Monoclonal Antibody Targeting Fusion Glycoprotein Function Protects Ferrets Against Lethal Nipah Virus and Hendra Virus Infection., PMID:31686101
An antibody against the F glycoprotein inhibits Nipah and Hendra virus infections., PMID:31570878
Henipavirus-like particles induce a CD8 T cell response in C57BL/6 mice., PMID:31561922
A single-dose ChAdOx1-vectored vaccine provides complete protection against Nipah Bangladesh and Malaysia in Syrian golden hamsters., PMID:31170144
Rabies-based vaccine induces potent immune responses against Nipah virus., PMID:31016033
Construction of the safe neutralizing assay system using pseudotyped Nipah virus and G protein-specific monoclonal antibody., PMID:30995971
Protection from Hendra virus infection with Canarypox recombinant vaccine., PMID:29263849
Two highly similar LAEDDTNAQKT and LTDKIGTEI epitopes in G glycoprotein may be useful for effective epitope based vaccine design against pathogenic Henipavirus., PMID:26970211
Structural characterization by transmission electron microscopy and immunoreactivity of recombinant Hendra virus nucleocapsid protein expressed and purified from Escherichia coli., PMID:26196500
Novel Functions of Hendra Virus G N-Glycans and Comparisons to Nipah Virus., PMID:25948743
Rhabdovirus-based vaccine platforms against henipaviruses., PMID:25320306
Hendra virus vaccine, a one health approach to protecting horse, human, and environmental health., PMID:24572697
Henipavirus microsphere immuno-assays for detection of antibodies against Hendra virus., PMID:24508193
Crystal structure of the Hendra virus attachment G glycoprotein bound to a potent cross-reactive neutralizing human monoclonal antibody., PMID:24130486
A treatment for and vaccine against the deadly Hendra and Nipah viruses., PMID:23838047
Biochemical, conformational, and immunogenic analysis of soluble trimeric forms of henipavirus fusion glycoproteins., PMID:22915804
Henipavirus mediated membrane fusion, virus entry and targeted therapeutics., PMID:22470837
Rapid screening for entry inhibitors of highly pathogenic viruses under low-level biocontainment., PMID:22396728
Ephrin-B2 and ephrin-B3 as functional henipavirus receptors., PMID:22227101
Characterization of germline antibody libraries from human umbilical cord blood and selection of monoclonal antibodies to viral envelope glycoproteins: Implications for mechanisms of immune evasion and design of vaccine immunogens., PMID:22226962
For research use only. Not for human or drug use.
